Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc > Enough Is enough
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by Year3000on Jan 14, 2024 5:53pm
73 Views
Post# 35826201

RE:RE:RE:RE:RE:RE:RE:Enough Is enough

RE:RE:RE:RE:RE:RE:RE:Enough Is enough

I took a huge loss but decided I was best to escape with some dignity! 

The company has said the injector is coming soon for the last 5 years, they have no trials on the go, they lost the shiseido case and they removed the product pipeline from their website; so where does the company go from here?

I just can't answer that? 

I don't believe some of the comments made in the AGM so where does it leave us? And we still haven't heard anything after such an important court hearing.

I think Andrew will probably buy more shares and/or take it private. 

someone feel free to correct if I'm wrong but I don't see where the value comes from anymore! 

I just saw better opportunities elsewhere and was getting FOMO. 

I first got in to investing because of Replicel it was something I really wanted to be a part of and it was a toss up between Replicel and Tesla. 

If id put the money in Tesla I'd be up 250k and it's haunted me ever since! I don't want finish on 0 and have diversified my portfolio some more! 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities